Skip to main content
SpringerLink
Log in

Anatomie und Pathologie der zentralen Gallengangstumoren

Anatomy and pathology of perihilar extrahepatic bile duct tumors (Klatskin tumors)

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Adenokarzinome der Gallengänge (sog. Cholangiokarzinome) können von den intrahepatischen und extrahepatischen Gängen ausgehen und sind seltene Tumoren. Als besondere Tumorentität wurden Karzinome der perihilären oder zentralen extrahepatischen Gallengänge (sog. Klatskin-Tumoren) abgegrenzt. Patienten mit solchen Karzinomen haben eine schlechte Prognose. Da die operativen Möglichkeiten sich ebenso verbessert haben wie die konservat iven Therapieansätze, wurden differenzierte TNM-Klassifikationen für Karzinome der verschiedenen Abschnitte des Gallengangssystems eingeführt, um die anatomische Ausbreitung möglichst genau beschreiben zu können. Die in der 7. Auflage der TNM-Klassifikation maligner Tumoren eingeführten neuen Klassifikationen bzw. Änderungen bestehender Klassifikationen beruhen auf Daten aus Asien und den USA. Die neue Klassifikation soll ab 01.01.2010 verbindlich angewendet werden.

Abstract

Adenocarcinomas of the bile ducts (so-called cholangiocarcinomas) may originate from both intrahepatic and extrahepatic bile ducts and constitute a rare tumor entity. Carcinomas of the perihilar and central extrahepatic bile ducts (so-called Klatskin’s tumors) are demarcated as special tumor entities and patients with these carcinomas face a poor prognosis. As therapeutic options have improved with respect to both operative and conservative treatment strategies, sophisticated TNM classifications for the different parts of the bile duct system have been introduced in order to determine the anatomic spread as accurately as possible. The new classifications and modifications of the 7th edition are based on data from Asia and the U.S. Application of the new classifications is mandatory as of 1st January 2010.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. AJCC (American Joint Committee on Cancer) (2009) In: Edge SB, Byrd DR, Compton CC et al (Hrsg) Cancer Staging Manual, 7. Aufl. Springer, New York

  2. Albores-Saavedra J, Henson DE, Klimstra DS (2000) Armed Forces Institute of Pathology: Atlas of Tumour Pathology. Tumours of the gallbladder, extrahepatic bile ducts, and Ampulla of Vater. AFIP, Washington

  3. Argani P, Shaukat A, Kaushal M et al (2001) Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 91:1332–1341

    Article  CAS  PubMed  Google Scholar 

  4. Benckert C, Jonas S, Cramer T et al (2003) Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63:1083–1092

    CAS  PubMed  Google Scholar 

  5. Bheerappa N, Sastry RA (2001) Pancreatico-biliary ductal union. Trop Gastroenterol 22:190–193

    CAS  PubMed  Google Scholar 

  6. Chung C, Bautista N, O’Connell TX (1998) Prognosis and treatment of bile duct carcinoma. Ann Surg 64:921–925

    CAS  Google Scholar 

  7. Fritz A, Percy C, Jack A et al (Hrsg) (2000) International Classification of Diseases for Oncology (ICD-0), 3. Aufl. WHO, Geneva

  8. Hamilton SR, Aaltonen LA (Hrsg) (2000) WHO: Pathology and Genetics. Tumours of the Digestive System. IARC Press, Lyon, S 206–214

  9. Han C, Demetris AJ, Wu T et al (2004) Cyclooxygenase-2 and prostaglandin E2 promote cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of epidermal growth factor receptor and AKT. Hepatology 40:301A, Abstract 318

    Google Scholar 

  10. Hansel DE, Rahman A, Hidalgo M et al (2003) Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163:217–229

    CAS  PubMed  Google Scholar 

  11. Heinrich PC, Behrmann I, Haan S et al (2003) Principles of Interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20

    Article  CAS  PubMed  Google Scholar 

  12. Hong SM, Cho H, Lee OJ et al (2005) The number of metastatic lymph nodes in extrahepatic bile duct carcinoma as a prognostic factor. Am J Surg Pathol 29:1177–1183

    Article  PubMed  Google Scholar 

  13. Hong SM, Cho H, Moskaluk CA et al (2007) Measurement of the invasion depth of extrahepatic bile duct carcinoma: An alternative method overcoming the current T classification problems of the AJCC staging system. Am J Surg Pathol 31:199–206

    Article  CAS  PubMed  Google Scholar 

  14. Ince N, Monte SM de la, Wands JR (2000) Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 60:1261–1266

    CAS  PubMed  Google Scholar 

  15. Kakar S, Burgart LJ (2005) Tumours of the biliary system. Curr Diagn Pathol 11:34–43

    Article  Google Scholar 

  16. Klatskin G (1965) Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 38:241–256

    Article  CAS  PubMed  Google Scholar 

  17. Kubicka S (2004) Cholangiozelluläres Karzinom und Gallenblasenkarzinom. [Cholangiocellular and gallbladder carcinoma]. Z Gastroenterol 42:397–402

    Article  CAS  PubMed  Google Scholar 

  18. Lee JC, Lin PW, Lin YJ et al (1995) Analysis of K-ras gene mutations in periampullary cancers, gallbladder cancers and cholangiocarcinomas from paraffin-embedded tissue sections. J Formos Med Assoc 94:719–723

    CAS  PubMed  Google Scholar 

  19. Maeda T, Sepe P, Lahousse S et al (2003) Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 38:615–622

    Article  CAS  PubMed  Google Scholar 

  20. Maeda T, Taguchi K, Aishima S et al (2004) Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase overexpression in cholangiocarcinoma. Cancer Detect Prev 28:313–318

    Article  CAS  PubMed  Google Scholar 

  21. McGlynn KA, Tarone RE, El-Serag HB (2006) A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 15:1198–1203

    Article  PubMed  Google Scholar 

  22. Nathan H, Aloia TA, Vauthey JN (2009) A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 16:14–22

    Article  PubMed  Google Scholar 

  23. Nishio H, Nagino M, Oda K et al (2005) TNM classification for perihilar cholangiocarcinoma: comparison between 5th and 6th editions of the AJCC/UICC staging system. Langenbecks Arch Surg 390:319–327

    Article  PubMed  Google Scholar 

  24. Ogasawara S, Yano H, Higaki K et al (2001) Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol Res 20:97–113

    Article  CAS  PubMed  Google Scholar 

  25. Rijken AM, van Gulik TM, Polak MM et al (1998) Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. J Surg Oncol 68:187–192

    Article  CAS  PubMed  Google Scholar 

  26. Satyanarayana A, Manns MP, Rudolph KL (2004) Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 40:276–283

    Article  CAS  PubMed  Google Scholar 

  27. Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115–125

    Article  PubMed  Google Scholar 

  28. Tamada S, Shibahara H, Higashi M et al. (2006) MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 12:4257–4264

    Article  CAS  PubMed  Google Scholar 

  29. Tanaka S, Sugimachi K, Kameyama T et al (2003) Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 37:1122–1129

    Article  CAS  PubMed  Google Scholar 

  30. Tannapfel A, Wittekind CH (2001) Anatomy and pathology of intrahepatic and extrahepatic bile duct tumors. Pathologe 22:114–123

    Article  CAS  PubMed  Google Scholar 

  31. Terada T, Okada Y, Nakanuma Y (1996) Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 23:1341–1344

    Article  CAS  PubMed  Google Scholar 

  32. UICC (International Union against Cancer) (1978) TNM Classification of Malignant Tumours In: Harmer MH (Hrsg), 3. Aufl. enlarged and revised 1982. Geneva

  33. UICC (International Union against Cancer) (2002) TNM Classification of Malignant Tumours, In: Sobin LH, Wittekind Ch (Hrsg) 6. Aufl. Wiley & Sons, New York

  34. UICC (International Union against cancer) (2010) TNM Classification of Malignant Tumors, In: Sobin LH, Gospodarowicz MK, Wittekind Ch (Hrsg) 7. Aufl. Blackwell Publishing Ltd., Oxford [Deutsche Übersetzung: UICC (2010) TNM-Klassifikation maligner Tumoren. Herausgegeben und übersetzt von Wittekind Ch, Meyer HJ (Hrsg) Wiley VCH, Weinheim]

  35. Watanabe M, Asaka M, Tanaka J et al (1994) Point mutation of K-ras gene codon 12 in biliary tract tumours. Gastroenterology 107:1147–1153

    CAS  PubMed  Google Scholar 

  36. Wiedmann M, Schoppmeyer K, Witzigmann H et al (2005) Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen. Z Gastroenterol 43:305–315

    Article  CAS  PubMed  Google Scholar 

  37. Wiedmann M, Schoppmeyer K, Witzigmann H et al (2005) Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen. Z Gastroenterol 44:473–475

    Article  Google Scholar 

  38. Wistuba II, Albores-Saavedra J (1999) Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 6:237–244

    Article  CAS  PubMed  Google Scholar 

  39. Wistuba II, Gazdar AF, Roa I et al (1996) p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol 27:360–365

    Article  CAS  PubMed  Google Scholar 

  40. Wittekind Ch (2006) Residualtumorklassifikation in der Onkologie. Anwendungen und Probleme. Onkologe 12:803–813

    Article  Google Scholar 

  41. Wittekind Ch (2006) Extrahepatic biliary tract and the Ampulla of Vater cancers. In: Gospodarowicz MK, O’Sullivan B, Sobin LH (Hrsg) Prognostic factors in cancer, 3. Aufl. Wiley& Sons, New York, S 147–151

  42. Witzigmann H, Berr F, Ringel U et al (2006) Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg 244:230–239

    Article  PubMed  Google Scholar 

  43. Yamasaki S (2003) Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 10:288–291

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Institut für Pathologie, Universitätklinikum Leipzig, Liebigstraße 26, 04103, Leipzig, Deutschland

    C. Wittekind & B. Oberschmid

Authors
  1. C. Wittekind
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Oberschmid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Wittekind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wittekind, C., Oberschmid, B. Anatomie und Pathologie der zentralen Gallengangstumoren. Onkologe 16, 841–848 (2010). https://doi.org/10.1007/s00761-010-1878-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-010-1878-7

Schlüsselwörter

Keywords

Search

Navigation